Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine.
Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine.
复制标题
DOI：
10.1016/j.eclinm.2021.100928
复制
发表时间：
2021-06
影响因子：
15.1
通讯作者：
Ciliberto G
中科院分区：
文献类型：
--
作者：
Pellini R;Venuti A;Pimpinelli F;Abril E;Blandino G;Campo F;Conti L;De Virgilio A;De Marco F;Di Domenico EG;Di Bella O;Di Martino S;Ensoli F;Giannarelli D;Mandoj C;Manciocco V;Marchesi P;Mazzola F;Moretto S;Petruzzi G;Petrone F;Pichi B;Pontone M;Zocchi J;Vidiri A;Vujovic B;Piaggio G;Morrone A;Ciliberto G
文献数据表明，年龄、性别和体重指数（BMI）可能与疫苗免疫应答的差异有关。该研究的第一个目标是分析248名医护人员（HCW）接种第二剂BNT 162 b2疫苗后7天的抗体滴度。第二个目标是分析抗体滴度与年龄、性别、BMI和高血压的相关性。在Istituti Fisioterapici Ospitalieri（IFO），罗马，意大利接种的HCW中进行免疫原性评价。意大利国家疫苗接种运动于二零二一年初要求所有医护人员接种疫苗。研究入组了260名接种疫苗的HCW。所有符合条件的参与者被分配在两周内接受预激剂量，并在此后21天内接受加强剂量。在基线和第二剂疫苗接种后7天采集血液和鼻咽拭子。用商业荧光免疫分析法定量测定SARS-CoV-2的S1/S2抗原的IgG抗体。通过商业RT-PCR检测确定鼻咽拭子中是否存在SARS-Cov-2。分析了248例HWC，158例女性（63.7%）和90例男性（36.3%）。在接种第二剂BNT 162 b2疫苗后，99.5%的参与者产生了体液免疫应答。加强剂量后接种受试者中抗体的几何平均浓度（285.9 Au/mL，95% CI：249.5-327.7）高于人恢复期血清（39.4 Au/mL，95% CI：33.1-46.9），p<0.0001。通过纳入协变量，按年龄、性别和BMI多变量对Au/mL进行多变量线性回归分析。该分析表明，年龄（p<0.0001）和性别（p = 0.038）与疫苗接种后抗体应答的差异有统计学相关性，而BMI和高血压无统计学显著相关性（分别为p = 0.078和p = 0.52）。99.5%的HCW产生了体液免疫应答，女性和年轻参与者似乎具有增强的体液免疫应答能力。BMI和高血压似乎与疫苗免疫反应的差异无关。没有。
Literature data suggests that age, gender and body mass index (BMI) could be associated with difference in immune responses to vaccines. The first goal of the study was to analyze the antibody titre seven days after the second dose of BNT162b2 vaccine in a group of 248 healthcare workers (HCWs). The second goal was to analyze how antibody titre changes in correlation with age, gender, BMI and hypertension. An immunogenicity evaluation was carried out among HCWs vaccinated at the Istituti Fisioterapici Ospitalieri (IFO), Rome, Italy. All HCWs were asked to be vaccinated by the Italian national vaccine campaign at the beginning of 2021. 260 vaccinated HCWs were enrolled in the study. All eligible participants were assigned to receive the priming dose in two weeks’ time and the booster dose exactly 21 days thereafter. Blood and nasopharyngeal swabs were collected at baseline and 7 days after second dose of vaccine. Quantitative measurements of IgG antibodies against S1/S2 antigens of SARS-CoV-2 were performed with a commercial chemiluminescent immunoassay. Presence of SARS-Cov-2 in nasopharyngeal swab was determined by commercial RT-PCR testing. 248 HWCs were analyzed, 158 women (63.7%) and 90 men (36.3%). After the second dose of BNT162b2 vaccine, 99.5% of participants developed a humoral immune response. The geometric mean concentration of antibodies among the vaccinated subjects after booster dose (285.9 AU/mL 95% CI: 249.5–327.7) was higher than that of human convalescent sera (39.4 AU/mL, 95% CI: 33.1–46.9), with p<0.0001. Multivariate linear regression analysis of AU/mL by age, gender and BMI multivariate was performed by the inclusion of covariates. This analysis demonstrated that age (p<0.0001) and gender (p = 0.038) are statistically associated with differences in antibody response after vaccination, whereas BMI and hypertension have no statistically significant association (p = 0.078 and p = 0.52 respectively). 99.5% of HCW developed a humoral immune response and female and young participants seem to have an increased capacity to mount humoral immune responses. BMI and hypertension seem not associated with difference in immune response to the vaccine. None.
登录
查看更多内容
影响因子：
29
作者：
Drucker DJ
通讯作者：
Drucker DJ
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
8.9
作者：
Popkin, Barry M.;Du, Shufa;Shekar, Meera
通讯作者：
Shekar, Meera
影响因子：
3.5
作者：
Eliakim, A;Swindt, C;Cooper, DM
通讯作者：
Cooper, DM
影响因子：
20.3
作者：
Hao, Yi;O'Neill, Patrick;Cancro, Michael P.
通讯作者：
Cancro, Michael P.